Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) said on Monday that its Japanese partner Eisai Co Ltd (TYO:4523) presented new data at the 2026 Alzheimer's Association International Conference (AAIC) in London, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease.

The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care partners.

A Developing Topics session, 'Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations', highlighted findings from the lecanemab SC-AI development programme in early Alzheimer's disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience data.

Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved IV initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, regardless of the route of administration.

The subcutaneous dosing option may offer a convenient at-home alternative to IV infusion, with the potential to expand treatment access and support more flexible care delivery across healthcare settings.